Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.

Geevar T, Pai R, Chacko G, Malepathi K, Patel B, John J, Chacko AG, Balakrishnan R, John S.

Neurol India. 2018 Nov-Dec;66(6):1726-1731. doi: 10.4103/0028-3886.246275.

2.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

3.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
4.

Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.

Michaud K, de Tayrac M, D'Astous M, Duval C, Paquet C, Samassekou O, Gould PV, Saikali S.

PLoS One. 2016 Dec 28;11(12):e0168728. doi: 10.1371/journal.pone.0168728. eCollection 2016.

5.

IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.

Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.

Cancer Sci. 2018 Jul;109(7):2327-2335. doi: 10.1111/cas.13635. Epub 2018 Jun 15.

6.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.

7.

Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas.

Ikemura M, Shibahara J, Mukasa A, Takayanagi S, Aihara K, Saito N, Aburatani H, Fukayama M.

Histopathology. 2016 Aug;69(2):260-7. doi: 10.1111/his.12927. Epub 2016 Feb 23.

PMID:
26741321
9.

[Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].

Yao K, Duan Z, Hu Z, Bian Y, Qi X.

Zhonghua Bing Li Xue Za Zhi. 2014 Oct;43(10):663-7. Chinese.

PMID:
25567591
10.

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.

Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network.

Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.

PMID:
25407774
11.

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and The Role of PDGFRA Amplification as a Marker of Recurrence and Prognosis

Kaya Terzi N, Yılmaz İ, Öz AB.

Balkan Med J. 2018 Dec 28. doi: 10.4274/balkanmedj.2018.1221. [Epub ahead of print]

12.

Biomarker-driven diagnosis of diffuse gliomas.

Appin CL, Brat DJ.

Mol Aspects Med. 2015 Nov;45:87-96. doi: 10.1016/j.mam.2015.05.002. Epub 2015 May 21. Review.

PMID:
26004297
13.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

14.

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N.

Acta Neuropathol. 2012 Nov;124(5):615-25. doi: 10.1007/s00401-012-1031-3. Epub 2012 Aug 12.

PMID:
22886134
15.

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.

Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR.

Acta Neuropathol. 2017 Jun;133(6):1001-1016. doi: 10.1007/s00401-017-1690-1. Epub 2017 Mar 2.

16.

ATRX immunostaining predicts IDH and H3F3A status in gliomas.

Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Tabatabai G, Schittenhelm J.

Acta Neuropathol Commun. 2016 Jun 16;4(1):60. doi: 10.1186/s40478-016-0331-6.

17.

Molecular genetics of gliomas.

Appin CL, Brat DJ.

Cancer J. 2014 Jan-Feb;20(1):66-72. doi: 10.1097/PPO.0000000000000020. Review.

PMID:
24445767
18.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

19.

Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.

Ballester LY, Huse JT, Tang G, Fuller GN.

Hum Pathol. 2017 Nov;69:15-22. doi: 10.1016/j.humpath.2017.05.005. Epub 2017 May 23.

PMID:
28549927
20.

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W.

Acta Neuropathol. 2013 Sep;126(3):443-51. doi: 10.1007/s00401-013-1156-z. Epub 2013 Aug 1.

Supplemental Content

Support Center